## PFE: Pfizer, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.2% below STRENGTH zone (3.0-6.0%); PEG 3.77 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.65)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Pfizer Inc. $PFE Stock Holdings Cut by Amundi**
- Source: MarketBeat | 20251206T040942 | Neutral | Relevance: 99%
-  Amundi significantly reduced its stake in Pfizer Inc. by 28.1% in Q2, selling over 14 million shares, yet still retains a substantial holding of 37,447,516 shares valued at approximately $948.17 million. Despite beating EPS expectations in its latest earnings report, Pfizer missed revenue estimates, and analysts maintain a consensus "Hold" rating with an average target price of $28.39, influenced by varying individual ratings. The company offers a high dividend yield of 6.7% with a 100% payout ratio.

**2. Ossiam Boosts Stock Position in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251208T115541 | Somewhat-Bullish | Relevance: 99%
- Ossiam significantly increased its stake in Pfizer Inc. by 71.2% in the second quarter, making the biopharmaceutical company its 11th largest position. Other institutional investors have also adjusted their holdings, and the stock currently holds an average "Hold" rating from analysts with an average price target of $28.39. Pfizer recently reported strong quarterly earnings and declared a quarterly dividend of $0.43 per share.

**3. State Street Corp Cuts Holdings in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251209T132952 | Neutral | Relevance: 99%
-  State Street Corp decreased its stake in Pfizer Inc. by 0.2% during the second quarter, now holding 296,301,310 shares valued at $7.18 billion. Several other institutional investors have also adjusted their positions in Pfizer. The company recently released its quarterly earnings, beating analyst estimates, and announced a quarterly dividend.

**4. Pfizer Inc. $PFE Shares Sold by Gabelli Funds LLC**
- Source: MarketBeat | 20251209T094507 | Somewhat-Bullish | Relevance: 99%
-  Gabelli Funds LLC significantly reduced its stake in Pfizer Inc. (PFE) by 44.9% in Q2, selling 467,425 shares. Despite this, other major institutional investors like Vanguard and Norges Bank increased their holdings, with institutional ownership now at 68.36%. Pfizer reported strong quarterly EPS of $0.87, beat analyst estimates, and announced a quarterly dividend of $0.43, offering a 6.7% yield.

**5. Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma**
- Source: Business Wire | 20251209T113311 | Bullish | Relevance: 98%
- Pfizer Inc. has announced an exclusive global collaboration and license agreement with YaoPharma for the development, manufacturing, and commercialization of YP05002, a small molecule GLP-1 receptor agonist in Phase 1 development for chronic weight management. Under the agreement, YaoPharma will receive an upfront payment of $150 million and is eligible for up to $1.935 billion in milestone payments, along with tiered royalties. This collaboration aims to advance Pfizer's portfolio in cardiometabolic diseases and explore combination studies with other pipeline molecules.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Valuation stretched: PEG 3.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.77 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (1 raises, avg +6%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $146.5B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.77 |
| Forward P/E | 8.3 |
| Current P/E | 8.2 |
| YoY Growth | -1.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.8% to -0.2% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.2pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Outperforming sector by 3.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.24% (CS: 53) | Neutral |
| RSI_14 | 56.3 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.024x | Above |
| vs SMA200 | 1.050x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.77
- **Stop Loss:** $24.65 (4.3% risk)
- **Target:** $26.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 446
- **Position Value:** $11,493.42
- **Portfolio %:** 11.49%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*